4-溴-3,5-二氯三氟甲苯 | 118754-53-3

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟甲苯系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-3,5-二氯三氟甲苯
• 中文别名: 3,5-二氯-4-溴三氟甲苯；2-溴-二氟甲氧基苯
• 英文名称: 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene
• 英文别名: 1-bromo-2,6-dichloro-4-trifluoromethylbenzene；2,6-dichloro-4-trifluromethylbromobenzene；4-bromo-3,5-dichlorobenzotrifluoride
• CAS: 118754-53-3
• 化学式: C₇H₂BrCl₂F₃
• 分子量: 293.898
• InChiKey: IQHSSYROJYPFDV-UHFFFAOYSA-N

物化性质

• 沸点：
  91-92 °C/10 mmHg
• 密度：
  1.833 g/mL at 25 °C
• 闪点：
  >230 °F
• 稳定性/保质期：
  稳定

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2903999090
• 危险性防范说明：
  P264,P270,P273,P301+P312,P330
• 危险性描述：
  H302,H413
• 储存条件：
  请将贮藏器保持密封，并存放在阴凉、干燥处。确保工作环境有良好的通风或排气设施。

SDS

Name:	4-Bromo-3 5-dichlorobenzotrifluoride Material Safety Data Sheet
Synonym:	None Known
CAS:	118754-53-3

Section 1 - Chemical Product MSDS Name:4-Bromo-3 5-dichlorobenzotrifluoride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
118754-53-3	4-Bromo-3,5-dichlorobenzotrifluoride	97	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 118754-53-3: Personal Protective Equipment Eyes: Wear chemical splash goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 100 deg C @ 4 mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6BrF3N2
Molecular Weight: 254.9546

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 118754-53-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-3,5-dichlorobenzotrifluoride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 118754-53-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 118754-53-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 118754-53-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-3,5-二氯三氟甲苯 在 sodium hypochlorite 、 四(三苯基膦)钯 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 24.0h， 生成 3-tert-butyl-5-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4,5-dihydroisoxazole
  参考文献：
  名称：

  氟苯腈激发的异恶唑啉和异恶唑的合成

  摘要：

  摘要 已知苯基吡唑（或芳基吡唑）作为GABA受体上的GABA门控氯离子通道的非竞争性抑制剂极为有效。该项目涉及合成新型异恶唑和异恶唑啉杂环，它们的结构特征与市售的苯基吡唑氟虫腈相似。合成适当取代的苯乙烯和苯乙炔后，再与几种脂肪族腈氧化物进行1,3-偶极环加成反应，这些化合物是由醛肟与漂白剂原位制备的。确定了这些专门的烯烃和炔烃双亲亲试剂的相对反应速率。 已知苯基吡唑（或芳基吡唑）作为GABA受体上的GABA门控氯离子通道的非竞争性抑制剂极为有效。该项目涉及合成新型异恶唑和异恶唑啉杂环，它们的结构特征与市售的苯基吡唑氟虫腈相似。合成适当取代的苯乙烯和苯乙炔后，再与几种脂肪族腈氧化物进行1,3-偶极环加成反应，这些化合物是由醛肟与漂白剂原位制备的。确定了这些专门的烯烃和炔烃双亲亲试剂的相对反应速率。

  DOI：

  10.1055/s-0034-1378737
• 作为产物：
  描述：

  2,6-二氯-4-三氟甲基苯胺 在 亚硝酸特丁酯 、 copper(ll) bromide 作用下， 以 乙腈 为溶剂， 以85%的产率得到4-溴-3,5-二氯三氟甲苯
  参考文献：
  名称：

  氟苯腈激发的异恶唑啉和异恶唑的合成

  摘要：

  摘要 已知苯基吡唑（或芳基吡唑）作为GABA受体上的GABA门控氯离子通道的非竞争性抑制剂极为有效。该项目涉及合成新型异恶唑和异恶唑啉杂环，它们的结构特征与市售的苯基吡唑氟虫腈相似。合成适当取代的苯乙烯和苯乙炔后，再与几种脂肪族腈氧化物进行1,3-偶极环加成反应，这些化合物是由醛肟与漂白剂原位制备的。确定了这些专门的烯烃和炔烃双亲亲试剂的相对反应速率。 已知苯基吡唑（或芳基吡唑）作为GABA受体上的GABA门控氯离子通道的非竞争性抑制剂极为有效。该项目涉及合成新型异恶唑和异恶唑啉杂环，它们的结构特征与市售的苯基吡唑氟虫腈相似。合成适当取代的苯乙烯和苯乙炔后，再与几种脂肪族腈氧化物进行1,3-偶极环加成反应，这些化合物是由醛肟与漂白剂原位制备的。确定了这些专门的烯烃和炔烃双亲亲试剂的相对反应速率。

  DOI：

  10.1055/s-0034-1378737

文献信息

• [EN] CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES CARBOCYCLIQUES DU RÉCEPTEUR GLYT1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011023667A1

  公开（公告）日：2011-03-03

  The present invention relates to the use of a compound of general formula (I) wherein R1/R2 are independently from each other hydrogen, lower alkyl, -CH2)o-cycloalkyl for o being 0 or 1, or are benzyl or heterocycloalkyl; or R1 and R2 are together with the N-atom to which they are attached a ring containing -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2-S-(CH2)2-, -(CH2)2-NR-(CH2)2-, -(CH2)2-C(O)-(CH2)2-, -(CH2)2-CF2-(CH2)2-, -CH2-CHR-(CH2)2, -CHR-(CH2)3, CHR-(CH2)2-CHR-, or is the ring 2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester and R is hydroxy, halogen, cycloalkyl, or C(O)O-lower alkyl; X is -(CH2)4-, -(CH2)3-, -(CH2)2- or -CH2-; R3 is S-lower alkyl, CF3, OCHF2, lower alkoxy, lower alkyl, phenyl, cycloalkyl or halogen; R4 is CF3, lower alkoxy, lower alkyl, halogen and n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers thereof for the manufacture of a medicament for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

  本发明涉及一种通式(I)的化合物的使用，其中R1/R2分别独立地为氢、较低的烷基、-CH2)o-环烷基，其中o为0或1，或者为苄基或杂环烷基；或者R1和R2与它们连接的N原子一起形成一个含有-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)2-O-(CH2)2-、-(CH2)2-S-(CH2)2-、-(CH2)2-NR-(CH2)2-、-(CH2)2-C(O)-(CH2)2-、-(CH2)2-CF2-(CH2)2-、-CH2-CHR-(CH2)2、-CHR-(CH2)3、CHR-(CH2)2-CHR-的环，或者是环2,6-二氮杂螺[3.3]庚烷-2-羧酸叔丁基酯，R为羟基、卤素、环烷基或C(O)O-较低烷基；X为-(CH2)4-、-(CH2)3-、-(CH2)2-或-CH2-；R3为S-较低烷基、CF3、OCHF2、较低烷氧基、较低烷基、苯基、环烷基或卤素；R4为CF3、较低烷氧基、较低烷基、卤素，n为1或2；或者用于制备用于治疗精神病、疼痛、记忆和学习功能障碍、注意力缺陷、精神分裂症、痴呆症或阿尔茨海默病的药物的药学上可接受的酸盐、外消旋混合物或其相应的对映体和/或光学异构体。
• CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS
  申请人：Kolczewski Sabine

  公开号：US20110053904A1

  公开（公告）日：2011-03-03

  The present invention relates to the use of a compound of formula I wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

  本发明涉及使用式I的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，X和n如本文所定义 或其药学上可接受的酸盐，或其相应的对映体和/或光学异构体，用于治疗精神病、疼痛、记忆和学习功能障碍、注意力缺陷、精神分裂症、痴呆症或阿尔茨海默病。
• Pesticidal method using 2-phenylimidazole derivatives
  申请人：May & Baker Limited

  公开号：US05206257A1

  公开（公告）日：1993-04-27

  The invention provides a method for the control of arthropod, plant nematode, helminth or protozoan pests using a 2-phenylimidazole derivative of the formula: ##STR1## wherein R.sup.1 represents hydrogen, alkyl (optionally substituted by alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, cyano, carboxy or alkoxycarbonyl), R.sup.2 and R.sup.3, each represents hydrogen, halogen, nitro, carboxy, cyano, alkoxycarbonyl, alkanoyl, or optionally alkyl substituted carbamoyl or sulphamoyl, or amino (optionally substituted by alkyl, alkoxycarbonyl or alkanoyl) or a group R, RO, RS, RSO or RSO.sub.2 in which R represents alkyl (optionally substituted by halogen), and Ar represents a group of the formula: ##STR2## wherein R.sup.4 and R.sup.6 each represents halogen or a group R, RO, RS, RSO or RSO.sub.2, and R.sup.5, R.sup.7 and R.sup.8 each represents a substituent as defined for R.sup.4 and R.sup.6, or represents hydrogen, hydroxy, carboxy, nitro, cyano, amino, alkylamino (optionally substituted by alkyl, alkoxycarbonyl or alkanoyl), alkoxycarbonyl or alkanoyl or a pesticidally acceptable salt thereof, with the exclusion of compounds in which R.sup.2 and R.sup.3 simultaneously represent hydrogen atoms, compositions for use in the method and novel compounds of formula I.

  该发明提供了一种利用公式为2-苯基咪唑衍生物的方法来控制节肢动物、植物线虫、蠕虫或原生动物害虫：其中R.sup.1代表氢、烷基（可选地由烷氧基、烷基硫醚、烷基磺醚、烷基磺酰基、氰基、羧基或烷氧羰基取代）、R.sup.2和R.sup.3分别代表氢、卤素、硝基、羧基、氰基、烷氧羰基、烷酰基，或可选地取代的烷基取代的氨基甲酰基或磺酰基，或氨基（可选地由烷基、烷氧羰基或烷酰基取代）或R、RO、RS、RSO或RSO.sub.2基团，其中R代表烷基（可选地由卤素取代），Ar代表公式的基团：其中R.sup.4和R.sup.6分别代表卤素或R、RO、RS、RSO或RSO.sub.2基团，而R.sup.5、R.sup.7和R.sup.8分别代表如R.sup.4和R.sup.6所定义的取代基，或代表氢、羟基、羧基、硝基、氰基、氨基、烷基氨基（可选地由烷基、烷氧羰基或烷酰基取代）、烷氧羰基或烷酰基或其农药可接受的盐，排除R.sup.2和R.sup.3同时代表氢原子的化合物，以及用于该方法的组合物和公式I的新化合物。
• Pyrazole derivatives and insecticidal compositions containing the
  申请人：Otsuka Kagaku Kabushiki Kaisha

  公开号：US05739083A1

  公开（公告）日：1998-04-14

  A pyrazole derivative represented by the formula (1) is low in toxicity and persistence and yet has an extremely high insecticidal efficacy ##STR1## wherein A is CH, N or C-halogen atom, R.sup.1 is hydrogen atom, lower alkyl, lower haloalkyl, benzyl or phenyl, R.sup.2 is lower alkyl, lower haloalkyl, lower alkenyl, lower alkynyl, benzyl or phenyl, R.sup.3 is hydrogen atom, a halogen atom lower alkyl, lower haloalkylthio, phenyl, cyano, nitro or amino, R.sup.4 is halogen atom, R.sup.5 is lower haloalkyl, R.sup.6 is hydrogen atom, lower alkyl, lower haloalkyl or benzyl, R.sup.1 and R.sup.6 being not hydrogen atoms at the same time, l is 0 or 1, m is 0 or 1 and n is a number of 0 to 2.

  式（1）表示的吡唑衍生物具有低毒性和低残留性，但具有极高的杀虫效力。其中，A为CH、N或C-卤素原子，R1为氢原子、低烷基、低卤代烷基、苄基或苯基，R2为低烷基、低卤代烷基、低烯基、低炔基、苄基或苯基，R3为氢原子、卤素原子、低烷基、低卤代烷基硫、苯基、氰基、硝基或氨基，R4为卤素原子，R5为低卤代烷基，R6为氢原子、低烷基、低卤代烷基或苄基，R1和R6不能同时为氢原子，l为0或1，m为0或1，n为0到2的数字。
• [EN] POTASSIUM ION CHANNEL MODULATORS & USES THEREOF<br/>[FR] MODULATEURS DES CANAUX D'IONS DU POTASSIUM ET UTILISATIONS ASSOCIÉES
  申请人：LECTUS THERAPEUTICS LTD

  公开号：WO2010010380A1

  公开（公告）日：2010-01-28

  Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs thereof wherein: Ar1 and Ar2 are aryl or heteroaryl; a is 0 to 5; R1 is alkyl, halogen, haloalkyl, alkoxy, haloalkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monoalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino or cyano and, where a is greater than 1, each substituent R1 may be the same or different; b is 0 to 5; R2 is alkyl, halogen, haloalkyl, haloalkoxy, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monoalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino or cyano and where b is greater than 1, each substituent R2 may be the same or different; V is selected from the group consisting of (CR3aR3b)pCON(R3b)X and (CR3aR3b)pN(R3b)CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z; W is selected from the group consisting of NR4a, O, S, S=O, SO2 and C(R4aR4b)2; X is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aryloxyalkyl, cycloalkyl, aryl, heteroaryl, polyalkylene glycol, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkyl that is substituted with a groups of formula of formula NR8R9 wherein R8 and R9 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated heterocyclic group, carboxyalkyl, alkoxycarbonylalkyl, haloalkoxycarbonylalkyl or aralkyloxycarbonylalkyl; Y and Z are the same or different and each is a substituent selected from the group consisting of (CR5aR5b)n1, C=O, SO2, C(=O)NR5a; C(=O)NR5aSO2 and C=O(R5aR5b)n2; R3a, R3b, R4a, R4b, R5a and R5b are the same or different and each is selected from the hydrogen, alkyl, cycloalkyl, aryl and heteroaryl; n1 and n2 are the same or different and each is 0 to 2; and p is 0 to 2; are potassium ion channel modulators, making them particularly useful in treating and preventing conditions such as pain, lower urinary tract disorders and the like.

  化合物公式（I）及其药学上可接受的盐和前药，其中：Ar1和Ar2是芳基或杂芳基；a为0至5；R1为烷基，卤素，卤代烷基，烷氧基，卤代烷氧基，烷氧羰基，羧基，羟基，氨基，单烷基氨基，双烷基氨基，硝基，酰胺基，烷氧羰基胺基，烷基磺酰基，烷基磺酰胺基或氰基，当a大于1时，每个取代基R1可以相同或不同；b为0至5；R2为烷基，卤素，卤代烷基，卤代烷氧基，烷氧基，烷氧羰基，羧基，羟基，氨基，单烷基氨基，双烷基氨基，硝基，酰胺基，烷氧羰基胺基，烷基磺酰基，烷基磺酰胺基或氰基，当b大于1时，每个取代基R2可以相同或不同；V从以下群组中选择：（CR3aR3b）pCON（R3b）X和（CR3aR3b）pN（R3b）CO（X），其中所述群组在取代基Z的3-（meta）或4-（para）位置上选择；W从以下群组中选择：NR4a，O，S，S=O，SO2和C（R4aR4b）2；X为氢，烷基，羟基烷基，烷氧基烷基，卤代烷氧基烷基，芳氧基烷基，环烷基，芳基，杂芳基，多烷基氧基乙烯，氨基烷基，单烷基氨基烷基，双烷基氨基烷基，烷基，该烷基被公式NR8R9的基团取代，其中R8和R9与它们所连接的氮原子形成饱和或部分不饱和的杂环基团，羧基烷基，烷氧羰基烷基，卤代烷氧羰基烷基或芳基氧羰基烷基；Y和Z相同或不同，每个都是从以下取代基中选择：（CR5aR5b）n1，C=O，SO2，C（=O）NR5a；C（=O）NR5aSO2和C=O（R5aR5b）n2；R3a，R3b，R4a，R4b，R5a和R5b相同或不同，每个都是从氢，烷基，环烷基，芳基和杂芳基中选择；n1和n2相同或不同，每个为0至2；p为0至2；是钾离子通道调节剂，使它们在治疗和预防疼痛，下尿路障碍等疾病方面特别有用。